Clinical Trials Browser

Oligoprogressive × pembrolizumab × 30 days × Clear all

NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

Phase 2 Terminated

16 enrolled 13 charts

Oligoprogressive